Neurobo Pharmaceuticals Inc
NASDAQ:NRBO
Intrinsic Value
NeuroBo Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in developing and commercializing multi-modal disease-modifying therapies. [ Read More ]
The intrinsic value of one NRBO stock under the Base Case scenario is 4.57 USD. Compared to the current market price of 3.45 USD, Neurobo Pharmaceuticals Inc is Undervalued by 25%.
Valuation Backtest
Neurobo Pharmaceuticals Inc
Run backtest to discover the historical profit from buying and selling NRBO stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Neurobo Pharmaceuticals Inc
Current Assets | 22.5m |
Cash & Short-Term Investments | 22.4m |
Other Current Assets | 77k |
Non-Current Assets | 269k |
PP&E | 248k |
Other Non-Current Assets | 21k |
Current Liabilities | 6m |
Accounts Payable | 821k |
Accrued Liabilities | 4.5m |
Other Current Liabilities | 658k |
Non-Current Liabilities | 136k |
Other Non-Current Liabilities | 136k |
Earnings Waterfall
Neurobo Pharmaceuticals Inc
Revenue
|
0
USD
|
Operating Expenses
|
-15.9m
USD
|
Operating Income
|
-15.9m
USD
|
Other Expenses
|
3.4m
USD
|
Net Income
|
-12.5m
USD
|
Free Cash Flow Analysis
Neurobo Pharmaceuticals Inc
What is Free Cash Flow?
NRBO Profitability Score
Profitability Due Diligence
Neurobo Pharmaceuticals Inc's profitability score is 37/100. The higher the profitability score, the more profitable the company is.
Score
Neurobo Pharmaceuticals Inc's profitability score is 37/100. The higher the profitability score, the more profitable the company is.
NRBO Solvency Score
Solvency Due Diligence
Neurobo Pharmaceuticals Inc's solvency score is 59/100. The higher the solvency score, the more solvent the company is.
Score
Neurobo Pharmaceuticals Inc's solvency score is 59/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
NRBO Price Targets Summary
Neurobo Pharmaceuticals Inc
Ownership
NRBO Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
NRBO Price
Neurobo Pharmaceuticals Inc
Average Annual Return | -69.78% |
Standard Deviation of Annual Returns | 29.33% |
Max Drawdown | -100% |
Market Capitalization | 16.9m USD |
Shares Outstanding | 4 906 030 |
Percentage of Shares Shorted | 2.98% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
NeuroBo Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in developing and commercializing multi-modal disease-modifying therapies. The company is headquartered in Boston, Massachusetts and currently employs 5 full-time employees. The company went IPO on 2016-08-05. The firm is engaged in the development and commercialization of therapeutics. The company is focused on four therapeutics programs designed to impact a range of indications in viral, neurodegenerative and cardiometabolic disease. The Company’s therapeutics programs include ANA001, NB-01, NB-02 and Gemcabene. Its ANA001, is an oral niclosamide formulation and was developed as a treatment for patients with moderate coronavirus disease (COVID-19). NB-01, which is primarily focused on the development of a treatment for painful diabetic neuropathy and treat a range of neuropathic conditions. Its NB-02, which treats the symptoms of cognitive impairment and modify the progression of neurodegenerative diseases associated with the malfunction of a protein called tau, and with amyloid beta plaque deposition. The Company’s Gemcabene, which is being assessed as an acute indication for COVID-19 treatments.
Contact
IPO
Employees
Officers
The intrinsic value of one NRBO stock under the Base Case scenario is 4.57 USD.
Compared to the current market price of 3.45 USD, Neurobo Pharmaceuticals Inc is Undervalued by 25%.